Cassava Sciences (SAVA) Competitors $1.62 +0.01 (+0.31%) As of 10:22 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SAVA vs. GLUE, PROK, ATAI, PHAT, ATYR, CYRX, ATXS, AQST, AURA, and ITOSShould you be buying Cassava Sciences stock or one of its competitors? The main competitors of Cassava Sciences include Monte Rosa Therapeutics (GLUE), ProKidney (PROK), Atai Life Sciences (ATAI), Phathom Pharmaceuticals (PHAT), Atyr PHARMA (ATYR), Cryoport (CYRX), Astria Therapeutics (ATXS), Aquestive Therapeutics (AQST), Aura Biosciences (AURA), and iTeos Therapeutics (ITOS). These companies are all part of the "pharmaceutical products" industry. Cassava Sciences vs. Monte Rosa Therapeutics ProKidney Atai Life Sciences Phathom Pharmaceuticals Atyr PHARMA Cryoport Astria Therapeutics Aquestive Therapeutics Aura Biosciences iTeos Therapeutics Cassava Sciences (NASDAQ:SAVA) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, community ranking, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation. Is SAVA or GLUE more profitable? Monte Rosa Therapeutics' return on equity of -62.68% beat Cassava Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Cassava SciencesN/A -88.05% -64.98% Monte Rosa Therapeutics N/A -62.68%-38.83% Does the media refer more to SAVA or GLUE? In the previous week, Monte Rosa Therapeutics had 3 more articles in the media than Cassava Sciences. MarketBeat recorded 5 mentions for Monte Rosa Therapeutics and 2 mentions for Cassava Sciences. Monte Rosa Therapeutics' average media sentiment score of 0.69 beat Cassava Sciences' score of 0.47 indicating that Monte Rosa Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cassava Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Monte Rosa Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings and valuation, SAVA or GLUE? Cassava Sciences has higher earnings, but lower revenue than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCassava SciencesN/AN/A-$97.22M-$1.45-1.12Monte Rosa Therapeutics$75.62M3.99-$135.35M-$1.02-4.80 Which has more risk and volatility, SAVA or GLUE? Cassava Sciences has a beta of -1.48, indicating that its stock price is 248% less volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500. Do insiders & institutionals believe in SAVA or GLUE? 38.0% of Cassava Sciences shares are owned by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. 9.0% of Cassava Sciences shares are owned by insiders. Comparatively, 6.5% of Monte Rosa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts rate SAVA or GLUE? Cassava Sciences currently has a consensus price target of $54.50, suggesting a potential upside of 3,264.20%. Monte Rosa Therapeutics has a consensus price target of $15.50, suggesting a potential upside of 216.33%. Given Cassava Sciences' higher possible upside, equities research analysts clearly believe Cassava Sciences is more favorable than Monte Rosa Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cassava Sciences 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Monte Rosa Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the MarketBeat Community favor SAVA or GLUE? Cassava Sciences received 82 more outperform votes than Monte Rosa Therapeutics when rated by MarketBeat users. Likewise, 64.47% of users gave Cassava Sciences an outperform vote while only 48.48% of users gave Monte Rosa Therapeutics an outperform vote. CompanyUnderperformOutperformCassava SciencesOutperform Votes9864.47% Underperform Votes5435.53% Monte Rosa TherapeuticsOutperform Votes1648.48% Underperform Votes1751.52% SummaryMonte Rosa Therapeutics beats Cassava Sciences on 10 of the 16 factors compared between the two stocks. Get Cassava Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SAVA vs. The Competition Export to ExcelMetricCassava SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$78.26M$6.85B$5.54B$7.93BDividend YieldN/A2.96%5.09%4.23%P/E Ratio-1.177.3222.5718.54Price / SalesN/A241.43399.89103.29Price / CashN/A65.8538.1834.62Price / Book0.506.486.774.25Net Income-$97.22M$143.41M$3.22B$248.18M7 Day Performance3.18%1.91%1.07%0.91%1 Month Performance16.55%4.28%2.46%2.58%1 Year Performance-92.66%-3.87%15.74%4.02% Cassava Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SAVACassava Sciences3.5753 of 5 stars$1.63+0.3%$54.50+3,253.8%-92.7%$78.50MN/A-1.1830Upcoming EarningsNews CoverageGLUEMonte Rosa Therapeutics1.9753 of 5 stars$4.94-2.5%$15.50+214.0%-17.5%$303.61M$75.62M-2.7090Upcoming EarningsShort Interest ↑News CoveragePositive NewsPROKProKidney2.2528 of 5 stars$1.04+1.5%$5.00+383.1%-60.5%$302.94M$76,000.00-1.883Upcoming EarningsGap UpATAIAtai Life Sciences2.6821 of 5 stars$1.46-0.3%$10.50+621.6%-28.3%$290.70M$308,000.00-1.8080Positive NewsPHATPhathom Pharmaceuticals3.8901 of 5 stars$4.19+1.8%$21.83+421.6%-63.7%$290.18M$55.25M-0.73110Analyst ForecastNews CoverageATYRAtyr PHARMA2.555 of 5 stars$3.27-2.5%$18.60+469.7%N/A$290.13M$235,000.00-3.4753Short Interest ↑Analyst RevisionNews CoverageGap UpCYRXCryoport2.6438 of 5 stars$5.70-1.0%$11.67+104.7%-67.5%$284.49M$228.39M-1.691,020Upcoming EarningsNews CoveragePositive NewsATXSAstria Therapeutics1.8827 of 5 stars$4.98-3.8%$26.60+434.7%-45.7%$280.76MN/A-2.3830Upcoming EarningsAnalyst UpgradeAnalyst RevisionNews CoverageAQSTAquestive Therapeutics1.6214 of 5 stars$2.83-1.6%$10.67+277.6%-10.8%$279.31M$57.56M-6.28160News CoverageAURAAura Biosciences2.3329 of 5 stars$5.49+2.1%$22.75+314.2%-20.7%$274.98MN/A-3.1650Upcoming EarningsShort Interest ↑News CoverageITOSiTeos Therapeutics2.0337 of 5 stars$7.04-4.2%$25.75+265.8%-36.3%$268.85M$35M-2.2390Earnings ReportUpcoming EarningsAnalyst ForecastAnalyst RevisionNews Coverage Related Companies and Tools Related Companies Monte Rosa Therapeutics Competitors ProKidney Competitors Atai Life Sciences Competitors Phathom Pharmaceuticals Competitors Atyr PHARMA Competitors Cryoport Competitors Astria Therapeutics Competitors Aquestive Therapeutics Competitors Aura Biosciences Competitors iTeos Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SAVA) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMassive dollar overhaul underway in D.C.?Trump's plan to save the U.S. Dollar The U.S. Dollar is crashing, and our reserve currency status is now in...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cassava Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SAVA Stock Free SAVA Stock Alerts